RocaJunyent advises Medsir on strategic alliance with Oncoclínicas

RocaJunyent and Athenea have advised Medsir on its strategic alliance with Oncoclínicas (owned by Goldman Sachs)

pjimage 2022 03 23T095938.490Athenea Healthcare Group, a consultancy specialised in the health sector, has led the comprehensive advice to MEDSIR in the operation, with the collaboration of RocaJunyent, who coordinated the legal advice.

Jochi Jiménez, partner of Athenea Healthcare Group, has highlighted on behalf of the team that: “We are very proud that we have been able to successfully complete an operation on which we have been working for many months and which means the consolidation of MEDSIR’s expansion worldwide and the first expansion operation of Oncoclinics in Europe. This alliance was created to improve research in the fight against cancer.”

On Monday, 21st March, the agreement was announced to the Brazilian stock market, whereby Oncoclínicas acquired 49% of MEDSIR for a fixed price of 5.75 million euros and an additional variable price of 3.5 million, that will be accrued depending on the fulfillment of certain business objectives. The transaction involves the direct investment of 2.75 million euros in the capital of MEDSIR to reinforce its international expansion both in Europe and in the USA, where it was already present.

The agreement also contemplates the possibility of additional capital injections over the next few years, in a clear commitment by Oncoclínicas to MEDSIR’s differential business model in the world of oncology clinical trials. With this alliance, MEDSIR also manages to land in the Latin American market and especially in the Brazilian market, which is the largest oncology market in Latin America. In addition, this agreement reflects Oncoclínicas’ global commitment to the fight against cancer and support for independent research.

This strategic alliance allows MEDSIR to consolidate its international expansion, which began five years ago, as well as become the leader of one of the best global research networks in oncology, since from now on it will have the collaboration of more than 1,500 specialists and the platform of genomics and diagnosis of Oncoclinics for the creation and design of new intelligent tests based on the experience of their leaders and on artificial intelligence.

The team from RocaJunyent was composed of partner Santi Pagès and senior associate Lourdes Amigó who advised during the operation.

Michael Heron